when the supply of the drug under trial was temporarily exhausted; a few additional cases were treated at the end of March when a further supply was received.
The cases were not selected, but, on admission, alternate cases were treated with anti-meningococcal serum (which series served as a control) and with the sulphone compound. All cases were admitted to the same ward and were under the immediate care of one of us (B. C. C.) who is in joint medical charge of the infectious diseases wards at the Campbell Hospital.
Cases in the drug-tested series were given orally 0.5 gramme of the sulphone glucoside compound every two hours up to a maximum ?f 3.0 grammes daily. Its Gram-negative diplococci resembling meningococci were seen to be present by microscopic examination in the cerebro-spinal fluid of all the patients included in the above series except one (case 69).
In The drug was non-toxic in the doses employed.
-The mortality rate in the cepticide series was 40 per cent, while that obtaining in the control series was 60 per cent. The number is too small to warrant the drawing of conclusions.
